Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA and FLU-QIV Co-administration Study in Older Adults
NCT04841577Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV), sponsored by GSK. Started Apr 2021; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04841577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04841577.